Pieri Luca, Porchia Barbara Rira, Pieralli Francesca, Varone Ornella, Niccolai Giuditta, Roselli Annalisa, Boccalini Sara, Bonanni Paolo, Bechini Angela
Scuola specializzazione in Igiene e medicina preventiva, Università di Firenze, Italy.
Dip. Prevenzione, ASL 4 Prato, Italy.
Epidemiol Prev. 2015 Jul-Aug;39(4 Suppl 1):119-23.
To assess the effectiveness of the varicella vaccination program in Toscana after one dose of vaccine, in the birth cohorts 2008-2011.
Varicella vaccine effectiveness (VE) was calculated using the "screening method", based on vaccine coverage (VC) at 24 months and proportion of vaccinated subjects among varicella notified cases (PVC), verified through the Local Health Units' (LHUs) immunization registries. Breakthrough varicella (BV) was defined as a case of varicella occurring in a child vaccinated ≥42 days before the date of disease onset.
The study was conducted in the 12 Tuscan LHUs and included all varicella cases notified in 2010-2013 in children of the birth cohorts 2008-2011.
BV cases; VE after one dose of varicella vaccine; time interval between varicella vaccination and symptom onset.
VC was 79.8%, VE reached 90.8%(95%CI 89.5%-92.0%) and the proportion of BV among notified cases was 26.6%. The median time interval between vaccination and symptom onset was 25 months.
The very low rate of BV cases among vaccinated children confirms the high effectiveness even of a single dose of varicella vaccine and does not support a change of the current immunization schedule.
评估2008 - 2011年出生队列在接种一剂疫苗后,托斯卡纳地区水痘疫苗接种计划的效果。
采用“筛查法”计算水痘疫苗有效性(VE),该方法基于24个月时的疫苗接种覆盖率(VC)以及水痘报告病例中接种疫苗者的比例(PVC),通过地方卫生单位(LHUs)的免疫登记进行核实。突破性水痘(BV)定义为在疾病发病日期前≥42天接种疫苗的儿童发生的水痘病例。
该研究在托斯卡纳的12个地方卫生单位进行,纳入了2010 - 2013年报告的2008 - 2011年出生队列儿童中的所有水痘病例。
突破性水痘病例;一剂水痘疫苗后的疫苗有效性;水痘疫苗接种与症状出现之间的时间间隔。
疫苗接种覆盖率为79.8%,疫苗有效性达到90.8%(95%可信区间89.5% - 92.0%),报告病例中突破性水痘的比例为26.6%。接种疫苗与症状出现之间的中位时间间隔为25个月。
接种疫苗儿童中突破性水痘病例的发生率极低,证实了即使单剂水痘疫苗也具有很高的有效性,不支持改变当前的免疫接种计划。